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SCIENTIFIC OPINION 
Scientific Opinion on the safety of “coriander seed oil” as a Novel Food 
ingredient
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver a scientific opinion on “coriander seed oil (CSO)” as a novel food 
ingredient (NFI) in the context of Regulation (EC) No 258/97. Petroselinic acid (PA) is the major fatty acid in 
CSO. Conventional edible oil technologies are used to manufacture the NFI. The NFI is intended to be marketed 
as a food supplement for healthy adults, at a maximum level of 600 mg per day (i.e. 8.6 mg/kg bw per day for a 
70 kg person), which would lead to significantly higher intakes of CSO and PA than current background intakes. 
There are no safety concerns regarding genotoxicity. In rats fed high amounts of CSO, increased liver weight, 
marked to severe fat infiltration in the liver, and lower tissue arachidonic acid concentrations were observed. In 
the same study, similar affects were observed when feeding other vegetable oils, although not as severe as that 
seen for CSO. The dose level of CSO was more than a thousand fold higher than the proposed use level. In a 
subchronic study using 150, 450 or 1 000 mg/kg bw per day of CSO, a treatment-related effect was observed on 
blood glucose concentrations of male rats. Although this effect was not accompanied by any toxicological 
findings, its biological relevance is unclear and therefore the Panel considers the dose level of 450 mg/kg bw per 
day to be the NOAEL in rats. This is more than 50 fold higher than the proposed use level. No treatment-related 
adverse effect was observed in one human study using the NFI at the proposed use level for six months. The 
Panel concludes that the novel food ingredient, CSO, is safe under the proposed uses and use levels.  
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on “coriander seed oil” as a novel food 
ingredient in the context of Regulation (EC) No 258/97, taking into account the comments and 
objections of a scientific nature raised by Member States.  
Coriander seed oil is a triglyceride oil, in which the monounsaturated fatty acid petroselinic acid is the 
main fatty acid (60-75 % of coriander seed oil). The novel food ingredient (NFI) also contains small 
quantities of other fatty acids such as linoleic acid, oleic acid, palmitic acid and stearic acid. The NFI 
is manufactured from seeds of Coriandrum sativum L. using conventional edible oil technologies. The 
applicant provided sufficient information regarding the composition, specification, manufacture and 
stability of the NFI. 
Coriander seed oil is intended to be marketed as a food supplement for healthy adults, at a maximum 
level of 600 mg per day. At this use level, the intake of coriander seed oil from the NFI is estimated to 
be about 30-40 times higher than estimated current mean background intake of coriander seed oil, 
while the intake of petroselinic acid is estimated to be about 15 times higher than the intake coming 
from estimated current background intake of this fatty acid.  
The applicant has provided in vitro genotoxicity studies on coriander seed oil. Based on the results of 
these studies, the Panel concludes that it has no safety concerns regarding genotoxicity. 
Data from rats receiving a diet containing 12 % coriander seed oil (approximately 12 g/kg bw per day) 
or other vegetable oils for 10 weeks indicate that triacylglycerols containing petroselinic acid are 
hydrolysed and absorbed from the small intestine, and that petroselinic acid is metabolised to the fatty 
acid cis-4-hexadecenoic acid. Incorporation of petroselinic acid into the adipose triacylglycerols of the 
rats receiving the coriander seed oil was observed. Increased liver weight, marked to severe fat 
infiltration in the liver, and lower tissue arachidonic acid concentrations were seen in a 10-week rat 
study using 12 % coriander seed oil in the diet. These effects are not unexpected when feeding animals 
with high levels of an oil that has a specific fatty acid profile. In the same study, feeding of olive oil, 
rapeseed oil, and sunflower oil at the same level also led to marked fat infiltration in the liver, 
although not as severe as that seen for coriander seed oil. The dose level of coriander seed oil was 
more than a thousand fold higher than the proposed use level of the NFI (i.e. 8.6 mg/kg bw per day for 
a 70 kg person). 
In a 13-week subchronic oral toxicity study in rats, 150, 450 or 1 000 mg/kg bw per day of coriander 
seed oil was given to three groups of 10 male and 10 female rats. A dose-dependent increase in serum 
glucose levels in males was observed, which reached statistical significance and was reported to be 
beyond background values at the high-dose level. No effect on serum glucose levels was seen in 
females. No other treatment-related effects were observed. Although the effect on glucose 
concentrations observed in male rats was not accompanied by any toxicologically relevant findings, 
the biological relevance of this effect is unclear and therefore the Panel considers that the dose level of 
450 mg/kg bw per day is the NOAEL in this study.  
Data from a controlled randomised double-blind study in healthy women, where participants received 
coriander seed oil at the intended use level for six months, showed no effect of coriander seed oil 
consumption on haematological parameters, nor on blood glucose and fatty acids concentrations, 
including arachidonic acid. No treatment-related adverse effect was observed. 
The risk of allergic reactions to the NFI is considered not to be higher than that of other products 
containing coriander seeds. 
There is a margin of more than 50 between the intended intake level of the NFI and the NOAEL of 
450 mg/kg bw per day determined in rats, and no treatment-related adverse effect was observed in one 
human study at the intended dose level. 
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The Panel concludes that the novel food ingredient, coriander seed oil, is safe under the proposed uses 
and use levels. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 21 July 2011, the company Nestec Ltd. submitted a request under Article 4 of the Novel Food Regulation 
(EC) N° 258/97 to place on the market “Coriander seed oil” as a novel food ingredient (NFI). 
On 19 October 2011, the competent authorities of Ireland forwarded to the Commission their initial 
assessment report, which came to the conclusion that coriander seed oil may be placed on the market.  
On 8 November 2011, the Commission forwarded the initial assessment report to the other Member States. 
Several of the Member States submitted comments or raised objections. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
 No data were provided on the level of tocopherols and other phenols.  
 No data were provided on the NFI content of volatile compounds, which are typically contained in 
coriander essential oil.  
 The bioavailability of petroselinic acid in the NFI vs. background diet should be considered in 
estimating the exposure.  
 Insufficient data was provided on the metabolism of petroselinic acid and its impact on other fatty 
acid bioavailability and metabolism (in particular, in view of its probable action on desaturases), at 
doses relevant to intended exposure.  
 Medium and long-term consequences have not been sufficiently evaluated, in particular with 
respect to potential accumulation of lipids in the liver (petroselinic acid appears to be a poor 
substrate for beta-oxidation and for hepatic lipase or hormone-sensitive lipase).  
 The results of a study in rats has shown both a reduction of arachidonic acid in several tissues and 
adverse effects on the liver (Weber et al., 1995; Richter et al., 1996). The relevance of these 
findings to human health has to be addressed.  
 The allergic potential of residual proteins or their degradation products contained in the NFI has to 
be further addressed.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority is asked to carry out the additional assessment for “Coriander seed oil” as a novel food 
ingredient in the context of Regulation (EC) No 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific 
nature in the comments raised by the other Member States. 
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ASSESSMENT 
In accordance with Commission Recommendation 97/618/EC
4
, coriander seed oil is allocated to Class 
2.1, i.e. “complex NF from non-GM source. The source of the NF has a history of food use in the 
Community”. The assessment of the safety of this novel food ingredient (NFI) is based on data 
supplied in the original application, the initial assessment by the competent authority of Ireland, the 
concerns and objections of the other Member States and the responses of the applicant. The data are 
required to comply with the information required for novel foods of Class 2.1, i.e. structured schemes 
I, II, III, IX, X, XI, XII and XIII of Commission Recommendation 97/618/EC. In the text these 
structured schemes are listed 1 to 8. The intention is to market coriander seed oil for use in food 
supplements for skin and hair benefits. This assessment only concerns risk that might be associated 
with consumption, and is not an assessment of the efficacy of coriander seed oil with regard to any 
claimed benefit. 
1. Specification of the Novel Food Ingredient (NFI) 
Coriander seed oil (CAS No. 8008-52-4) is a triglyceride oil that is produced from the seeds of the 
coriander plant Coriandrum sativum L.
5
. The product specifications are presented in Table 1. 
Petroselinic acid, a monounsaturated fatty acid, is the major fatty acid in coriander seed oil (60-75 % 
of the oil). Petroselinic acid (cis-6-octadecenoic acid, cis-C18:1(n-12)), is a regioisomer of oleic acid 
(cis-9-octadecenoic acid, cis-C18:1(n-9)). 
The NFI also contains small quantities of other fatty acids, such as linoleic acid (12-19 %), oleic acid 
(8-15 %), palmitic acid (2-5 %) and stearic acid (< 1.5 %). The applicant provided analyses (by 
accredited laboratories) of the fatty acid contents of 3 non-consecutive batches of the NFI, which 
complied with the specifications (Table 2). The applicant provided separated analyses of the trans 
fatty acid content of the three batches (0.26 %, 0.04 % and 0.27 %, respectively), which complied with 
the specification.  
Table 1:  Specifications for coriander seed oil, as proposed by the applicant 
 Specification
 
Method
 
Characteristics   
Colour Slight yellow NGD C20-1976 
Odour and taste Bland GI-31.107-1 
Refractive index (at 20°C) 1.466 to 1.474 IUPAC 2.102 
Acid value Max. 0.6 mg KOH/g Nestec LI-00.516 
Peroxide value Max. 5 meq/kg Nestec LI-03.512 
Iodine Value 88 to 102 units Nestec LI-03.507 
Saponification value 186 to 198 mg KOH/g NGD C8-1976 
Unsaponifiable matter Max. 15 g/kg IUPAC 2.401 
Composition of Fatty Acids   
Palmitic acid (C16:0) 2 to 5 % IUPAC 1.122 
Stearic acid (C18:0) < 1.5 % IUPAC 1.122 
Petroselinic acid (cis-C18:1(n-12)) 60 to 75 % IUPAC 1.122 
Oleic acid (cis-C18:1(n-9)) 8 to 15 % IUPAC 1.122 
                                                     
4  Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientific 
aspects and the presentation of information necessary to support applications for the placing on the market of novel foods 
and novel food ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the 
European Parliament and of the Council. OJ L 253, 16.9.1997, p. 1-36 
5
  Taxonomic classification: Kingdom: Plantae; Phylum: Magnoliophyta; Class: Magnoliopsida; Order: Apiales; Family: 
Apiaceae (Umbelliferae); Genus: Coriandrum L.; Species: Coriandrum sativum L. 
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 Specification
 
Method
 
Linoleic acid (C18:2) 12 to 19 % IUPAC 1.122 
α-Linolenic acid (C18:3) < 1.0 % IUPAC 1.122 
Trans Fatty Acids Max. 1% IUPAC 1.122 
IUPAC: International Union of Pure and Applied Chemistry; KOH: potassium hydroxide;  
Table 2:  Batch Analysis of fatty acid content of coriander seed oil  
 
Specification 
Batch IZXFK 
Batch 
IBRDF 
Batch 
JCAKG 
Petroselinic acid (cis-C18:1(n-12)) 60 to 75 % 71.41 67.5 62.08 
Linoleic acid (C18:2) 12 to 19 % 13.82 15.66 17.3 
Oleic acid (cis-C18:1(n-9)) 8 to 15 % 9.01 10.45 13.29 
Palmitic acid (C16:0) 2 to 5 % 3.19 3.68 4.02 
Stearic acid (C18:0) < 1.5 % 0.68 0.89 1.02 
α-Linolenic acid (C18:3) < 1.0 % 0.32 0.20 0.70 
Vaccenic acid (trans-C18:1(n-7)) n.a. 0.79 0.81 0.82 
Palmitoleic acid (C16:1) n.a. 0.33 0.33 0.28 
Arachidic acid (C20:0) n.a. 0.09 0.13 0.18 
Margaric acid (C17:0) n.a. 0.06 0.07 0.07 
Myristic acid (C14:0) n.a. 0.06 0.06 0.05 
Behenic acid (C22:0) n.a. 0.04 0.04 0.07 
Not identified n.a. 0.20 0.18 0.12 
Total fatty acids (%)  100 100 100 
 
The applicant also provided analyses of the characteristics of four non-consecutive batches of the NFI, 
which complied with the specifications (Table 3).  
Table 3:  Batch analysis of the characteristics of  coriander seed oil  
 Specification 
Batch 
IBRDF 
Batch 
JCAKH 
Batch 
JCDTH 
Batch 
JCDTI 
Refractive index (at 20°C) 1.466 to 1.474 1.471 1.472 1.472 1.472 
Acid value Max. 0.6 mg KOH/g 0.12 0.10 0.14 0.14 
Peroxide value Max. 5 meq/kg < 0.20 0.20 0.20 0.20 
Iodine value 88 to 102 units 99.0 99.5 98.8 98.8 
Saponification value 186 to 198 mg KOH/g 190 188 191 191 
Unsaponifiable matter Max. 15g/kg 11.60 13.88 9.42 9.42 
The NFI exhibits a content of total sterols ranging from 2.4 to 3.7 g/kg. The predominant phytosterols 
are ß-sitosterol, stigmasterol, campesterol and δ-7-stigmastenol.  
In three batches of the NFI, the protein content was lower than the limit of quantification (0.1 g/100 g) 
for the analytical method applied (Kjeldahl method). Following a request from a Member State (MS), 
an additional analysis was performed. The coriander seed oil was extracted with acetone-hexane 
followed by centrifugation and colorimetric quantification of the protein content. The level of protein 
in the five batches tested was below the detection limit of 1.5 mg/kg. 
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In response to a MS‟s request with respect to the tocopherol content of the NFI, the applicant provided 
the analytical results of 3 batches of the NFI, where tocopherols were below the limit of quantification 
(LOQ = 2 mg/100 g; analysed by HPLC).   
The NFI is obtained by hexane extraction (Section 2). Results of the analysis of potential residual 
levels of hexane have been provided for three batches of the NFI, and were all below the limit of 
quantification of 0.5 mg/kg. This is in accordance with the maximum residue limit of 1 mg hexane/kg 
set for fats, oils and cocoa butter in Directive 2009/32/EC
6
.  
Regarding heavy metals, dioxins/PCBs, polycyclic aromatic hydrocarbons (specifically 
benzo[a]pyrene) and pesticides residues, the applicant provided test results for three batches of the 
NFI, which were lower than the maximum levels set in Commission Regulation (EC) No 1881/2006
7
, 
or than the quantification limits for the analytical methods applied.  
In response to an MS‟s request concerning the presence of volatile compounds in the NFI, the 
applicant indicated that the oil undergoes vacuum deodorisation for 3.5 hours at 200 °C, and is 
therefore unlikely to contain any significant levels of such compounds. 
The Panel considers that the information provided on the composition, specification and data from 
batch testing do not raise safety concerns.  
Stability 
The NFI has to be stored in light protected and airtight conditions, under cool and dry conditions with 
temperature not exceeding 20 °C. Under these storage conditions, data provided by the applicant 
confirms that the NFI is stable for at least 12 months.  
The analyses of the acid value and the peroxide value of the NFI indicate that when stored under 
appropriate conditions, the coriander seed oil would not be significantly oxidised or hydrolysed. 
The Panel considers that the data provided sufficient information with respect to the stability of the 
NFI. 
2. Effect of the production process applied to the NFI  
Coriander seed oil is manufactured from seeds of the coriander plant Coriandrum sativum L.. Seeds 
are mechanically pressed, then processed on a rolling mill to obtain a flaked cake. The crude oil is 
extracted using hexane and neutralised with a sodium hydroxide solution. The oil is then washed with 
water and subsequently bleached with 1.5 % bleaching earth, 1.0 % activated carbon, and 0.5 % 
amorphous silica gel. The bleached oil is winterised with perlite 1200S to absorb impurities from the 
oil, and is deodorised with steam to obtain the fully refined coriander seed oil.  
The applicant provided the specifications for the coriander seeds used for the manufacturing process 
with respect to their oil content (> 20 %), water content (< 9 %), level of impurity (< 2 %) and broken 
seeds (< 5 %). The applicant indicates that the other materials are typically used in the oil refining 
industry. Activated carbon (Carbopal
®
) is used to remove dissolved organic compounds such as 
polycyclic aromatic hydrocarbons in oils, and for controlling odour and taste. Bleaching earth (Tonsil
®
 
Supreme 110 FF) is acidified, and is used to remove polar compounds via adsorption. Amorphous 
silica gel (TriSyl
®
) is also used in the refining of the oil.  
                                                     
6  Directive 2009/32/EC of the European Parliament and of the Council of 23 April 2009 on the approximation of the laws of 
the Member States on extraction solvents used in the production of foodstuffs and food ingredients (Recast) (Text with 
EEA relevance), OJ L 141, 6.6.2009, p. 3-11 
7  Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in 
foodstuffs, OJ L 364, 20.12.2006, p. 5-24. 
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The applicant‟s manufacturing subsidiary for speciality oils is independently certified to have a valid 
HACCP system in place in accordance with Regulation (EC) N. 852/2004
8
. The applicant also applies 
ISO 22000:2005
9
. 
The manufacturer uses conventional edible oil manufacturing procedures. The Panel concludes that 
the production process is sufficiently described and does not raise safety concerns.  
3. History of the organism used as a source  
The applicant indicates that the seeds used come from Coriandrum sativum L.. Ground or whole 
coriander seeds are commonly used as food seasonings (Kiralan et al., 2009). The ground seeds are 
one of the major constituents of curry powder. 
4. Anticipated intake/extent of the use of the NFI 
Coriander seed oil is proposed to be supplied as a food supplement at a maximum level of 600 mg per 
day (three 200 mg tablets per day; equivalent to 8.6 mg/kg bw/day for a 70 kg person).  
The applicant indicates that these supplements are intended for healthy adults. It is not aimed at 
children and pregnant and lactating women. 
5. Information from previous exposure to the NFI or its source 
Coriander-distilled essential oil has been in use as a food flavouring and fragrance ingredient since the 
1900s (Opdyke, 1973). Coriander essential oil also has a long history of use as a traditional medicine 
(Burdock and Carabin, 2009). Coriander essential oil has been approved for use in medicines (as 
active ingredient or excipient) and flavourings in Canada (Health Canada, 2007, 2009), Australia 
(Therapeutic Goods Administration, 2007) and the United States (U.S. FDA, 2011).  
Use of coriander seeds as a source of flavouring materials was considered by the Council of Europe, 
and was concluded to be acceptable for addition to foodstuffs as a herb, spice or seasoning with 
possible limitation of the active principle in the final product (Council of Europe, 1981).  
5.1. Background consumption of coriander seeds 
The applicant provided estimates of the background intakes of coriander seed in the UK population 
using consumption data from the UK National Diet and Nutrition Survey (NDNS). Alcoholic 
beverages (e.g. coriander-flavoured spirits) and curry powder were considered as the main sources of 
exposure. Calculations were based on the assumption that all curries consumed by individuals in the 
UK NDNS were made with curry powder containing 23 % coriander seed.  
Estimates of the daily intake of coriander seed were calculated at individual level, and represent 
projected 7-day averages. The distribution from which mean and high percentile intake estimates were 
produced was comprised of these average amounts. Results are provided in Table 4. 
  
                                                     
8  Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of 
foodstuffs, OJ L 139, 30.4.2004, P. 1-54 
9  ISO 22000:2005 specifies requirements for a food safety management system, for any organisation in the food chain. 
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Table 4: Summary of the estimated daily intake of coriander seed from all background food 
categories in the UK by population group (UK NDNS data) 
Population 
Group  
Age 
Group 
(Years)  
% 
User  
Actual 
Number 
of Total 
Users  
All-Person Consumption  All-Users Consumption 
Mean 
(mg)  
Percentile (mg)  
Mean 
(mg)  
Percentile (mg)  
90        95 97.5           90 95 97.5  
Children  1½ -4½  43.0  709  13  34  47  63  31  51  69  101  
Young People  4-10  62.2  521  36  61 118  249  58  95 206  323  
Female Teenager  11-18  64.1  286  95  115  519  998  127  149  697  1 051  
Male Teenager  11-18  69.5  289  100 147  605  1 117  139 286  933  1 128  
Female Adult  16-64  61.1  585  61  99  217  630  95  145  520  986  
Male Adult  16-64  67.6  518  76  128  254  810  104  172  486  991  
 
According to the applicant, coriander seeds contain up to 20 % oil. The estimated mean daily intake of 
coriander seed oil from intake of coriander seeds is thus around 15 and 20 mg for adult all-persons (i.e. 
total population) and adult all-users (i.e. consumers of coriander seeds containing products only), 
respectively. The intake coming from the proposed 600 mg coriander seed oil from supplements is 
about 30-40 times higher than the estimated mean background intake of coriander seed oil. For adult 
all-users in the 95
th
 percentile, the estimated daily intake of coriander seed oil from the intake of 
coriander seed is about 100 mg. 
5.2. Background consumption of petroselinic acid 
The applicant indicates that petroselinic acid is also present in other seeds for human consumption, 
including seeds from anise, dill, parsley, fennel and celery. Estimates of the background intakes of 
petroselinic acid were calculated using consumption data from the UK NDNS and ingredient lists of 
food product containing these seeds, such as alcoholic beverages, curry powders, industry-prepared 
curry sauces, pickles, seasonings and spice mixes and soup powders. The petroselinic acid content in 
seeds was derived from published literature sources, and based on the amount of fatty acids in the seed 
oil per seed type. The maximum percentage content of petroselinic acid from all seed types (18.1 %) 
was used in the calculation. The resulting estimated daily intake of petroselinic acid from all 
background food categories are shown in Table 5. 
Table 5: Summary of the estimated daily intake of petroselinic acid from all background food 
categories in the UK by population group (UK NDNS Data) 
Population Group  Age 
Group 
(Years)  
% 
User  
Actual 
Number 
of Total 
Users  
All-Person Consumption  All-Users Consumption  
Mean 
(mg)  
Percentile (mg)  Mean 
(mg)  
Percentile (mg)  
90 95 97.5  90   95 97.5 
Children  1½ -4½  77.2  1,273  10  21  28  36  12  24  30  43  
Young People  4-10  91.5  766  19  29  43  72  20  31  44  77  
Female Teenager  11-18 87.4  390  39  43  213  394  39  43  159  394  
Male Teenager  11-18 92.1  383  41  55  240  393  44  56  297  420  
Female Adult  19-64  80.4  770  25  32  57  234  29  35  110  271  
Male Adult  19-64  86.9  666  30  43  69  325  32  45  71  337  
 
According to the intake data provided by the applicant, the estimated mean daily intake of petroselinic 
acid from all background sources would be around 30 mg for adults. The amount of petroselinic acid 
(ca. 450 mg) coming from the proposed 600 mg coriander seed oil from supplements is about 15 times 
higher than the intake coming from estimated mean background intake of petroselinic acid. For adult 
all-users in the 95
th
 percentile, the daily intake of petroselinic acid is about 100 mg.  
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The Panel notes that these estimates are based on a number of assumptions which overestimate actual 
background intakes of coriander seed oil and petroselinic acid by the population. 
6. Nutritional information on the NFI 
The main constituent of the NFI is petroselinic acid, which is a monounsaturated fatty acid (60-75 % 
of coriander seed oil). Lower proportions of other fatty acids such as linoleic, oleic, palmitic and 
stearic acid are also present (Section 1). 
The applicant indicates that coriander seed oil is intended to be marketed as a food supplement and is 
not anticipated to replace other foods in the diet. 
The Panel considers that consumption of the NFI is not nutritionally disadvantageous.  
7. Microbiological information on the NFI 
The applicant provided results for three batches of the NFI. Total aerobic count and Enterobacteria 
were lower than the quantification limit (10 UFC/mL) and Salmonella spp. were absent in 25 g.  
The Panel considers that the microbiological information provided does not raise safety concern.  
8. Toxicological information on the NFI 
8.1. Absorption, Distribution, Metabolism and Excretion 
In a study by Heimermann et al. (1973), fifteen triacylglycerols, containing C12:0, C14:0, C16:0, 
C18:2 and positional isomers of cis-C18:1 fatty acids, were hydrolysed by pancreatic lipase and the 
resulting free fatty acids were analysed by gas liquid chromatography. The study indicated that the 
presence of a double-bond near the carboxyl group of an acid, like in petroselinic acid, slows its 
hydrolysis from a triacylglycerol. Another study by Seher and Fiebig (1983) also describes that the 
incubation (5 min) of model mixtures of petroselenic-containing triglycerols with pancreatic lipase and 
fungal lipases, respectively, resulted in maximum hydrolysis rates of 20 %. Thus, both of the two in 
vitro studies indicate that triacylglycerols containing petroselinoyl moieties are hydrolysed at slower 
rates than other triacylglycerols. 
A number of publications addressed the effects of a diet containing 12 % coriander oil (72 % 
petroselinic acid) given to rats for 10 weeks on hepatic lipid profile (Weber et al., 1997), the 
concentrations of arachidonic acid in body tissues (blood, liver, and heart) (Weber et al., 1995), and 
the distributions of fatty acid moieties contained within triacylglycerols of adipose tissue (Weber et al., 
1999; Weber et al., 2003). Considering the composition of the oil used, the Panel assumes that it was 
derived from coriander seeds. 
Groups of 10 male Wistar rats were administered coriander seed oil, olive oil, high-oleic sunflower oil 
(HOS), rapeseed oil, or conventional sunflower oil in the diet, at concentrations of 12 % for a period 
of 10 weeks (Weber et al., 1995). The Panel notes that this is equivalent to approximately 12 g/kg bw 
(EFSA SC, 2012). 
No early deaths were recorded, and body weights, food intake and efficiency were comparable among 
the  groups. Liver weights of rats in the coriander seed oil-treated group were significantly higher than 
in the four other groups. Liver lipid levels were significantly higher in the coriander and olive oil 
groups compared to the HOS group. Heart, spleen, kidney, and testes weights were comparable among 
all groups, as were levels of plasma total cholesterol, high-density lipid (HDL) cholesterol, and 
triacylglycerols. Rats in the coriander seed oil group had significantly lower levels of faecal 
triacylglycerols compared to the HOS and olive oil groups. No significant differences in fat absorption 
were seen between the groups. Rats fed coriander seed oil had petroselinic acid incorporated in their 
heart, liver and blood lipids, whereas arachidonic acid levels were significantly lower (up to 50 %) 
compared to the HOS group. Additionally, significantly higher levels of linoleic acid were observed in 
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tissue and blood lipids from the coriander seed oil group compared to the HOS group. Thus, the data 
indicate that in vivo the triglycerides in coriander seed oil are hydrolysed by lipases and petroselinic 
acid is absorbed. According to the authors, petroselinic acid at this high dose level partially inhibits the 
processes that lead to the formation of arachidonic acid (i.e. desaturation and chain elongation) in rats.   
In order to determine the metabolic fate of petroselinic acid in the liver, and its effect on hepatic lipid 
profile, groups of male Wistar rats (10 per group) were provided coriander or high-oleic sunflower oil 
in the diet at concentrations of 12 % for a period of 10 weeks (Weber et al., 1997). The coriander seed 
oil comprised petroselinic acid (72.4 %), linoleic acid (18.6 %), palmitic acid (5.4 %), oleic acid 
(2.5 %), stearic acid (0.4 %), and other fatty acids (0.7 %). In comparison, the high-oleic sunflower oil 
contained oleic acid (75.0 %), linoleic acid (14.7 %), palmitic acid (5.9 %), stearic acid (2.8 %), and 
other fatty acids (1.6 %). Following the 10-week test feeding period, rats were necropsied and the 
livers were removed and analysed for fatty acid composition of the lipid fraction.  
Petroselinic acid was only observed in the liver lipids from rats provided coriander seed oil. Likewise, 
only coriander seed oil-treated rats were observed to accumulate cis-8-eicosenoic acid (C20:1(n-12)) 
and cis-4-hexadecenoic acid (C16:1(n-12)) in their livers. Based on the absence of these two fatty 
acids in the high-oleic sunflower oil group, the authors suggested that petroselinic acid is subject to 
elongation, resulting in cis-8-eicosenoic acid, and β-oxidation, forming cis-4-hexadecenoic acid. No 
metabolites resulting from desaturation-elongation reactions were observed in the coriander seed oil-
fed group. In comparison to the high-oleic sunflower oil group, higher levels of linoleic acid were 
observed in the coriander seed oil group (16.1 % vs. 9.0 %), accompanied by lower levels of 
arachidonic acid (10.0 % vs. 16.7 %), suggesting that petroselinic acid interfers with synthesis of 
arachidonic acid from linoleic acid. According to the authors, inhibition may be the result of 
petroselinic acid inhibiting Δ-desaturase which converts linoleic acid to γ-linolenic acid by mimicking 
a product of Δ-desaturase. Overall, petroselinic acid was shown to be absorbed and primarily 
metabolised to cis-8-eicosenoic acid and cis-4-hexadecenoic acid. 
In two other papers by the same group (Weber et al., 1999; Weber et al., 2003), the fatty acid 
composition of adipose tissue (epididymal, subcutaneous and perirenal) of the rats was found to 
broadly reflect the fatty acid composition of the oils administered. It was shown that petroselinic acid 
from the coriander seed oil was extensively incorporated into adipose triacylglycerols. It was further 
demonstrated that also the regiospecific distribution of the major acyl moieties of the subcutaneous 
adipose tissue broadly reflected the distribution of the acyl moieties in the oils given to the rats.   
In another experiment, petroselinic acid, oleic acid and cis-C18:1(n-10) were given in concentrations 
up to 5 % of the diet to groups of six rats for three weeks, through a combination of parsley seed oil, 
sunflower seed oil, olive oil and ethyl-cis-8-octadecenoate (Hoy and Holmer, 1981). Diets differed in 
their content in octadecenoic acids but had similar contents of saturated, mono-unsaturated and poly-
unsaturated fatty acids. Petroselinic acid was shown to be incorporated into lipids in the liver and into 
adipose tissue, but at a slower rate than cis-C18:1(n-10). The fatty acids in the total lipids of adipose 
tissue were mirroring the dietary intake of fatty acids; no difference between groups was observed in 
the adipose tissue profile for the other major fatty acids analysed (C14:0, C16:0, C16:1, C18:0, 
C18:2). The fatty acids in the diet did not affect the amount of polyunsaturated fatty acids in the 
phospholipids of the liver mitochondrial membrane.  
The Panel concludes that triacylglycerols containing petroselinic acid appear to be hydrolysed in vivo 
and absorbed from the small intestine. Some data indicate that petroselinic acid is metabolised to the 
fatty acid cis-4-hexadecenoic acid (Weber et al., 1997). Coriander seed oil, at high concentrations (12 
% in the diet) and as the primary lipid source, appears to interfere with the formation of arachidonic 
acid from linoleic acid, probably through an effect on desaturation and elongation pathways (Weber et 
al., 1995; Weber et al., 1997). At high doses, lipid profiles of liver and other tissues have been 
observed to be altered (Weber et al., 1995; Weber et al., 1997; Weber et al., 1999; Weber et al., 2003). 
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Changes in liver tissue arachidonic acid concentrations or hepatic lipid profiles have also been 
observed with high doses of other fats and oils. In a study by Caster et al. (1966), rats were given diets 
with 10 % common natural fats or oils, and mixtures hereof for 66 days. The diets with the different 
fats and oils resulted in significant changes in the liver lipid profile. Feeding rats with up to 21 % of 
isomeric cis- and trans- octadecenoic acid in the diet lowered the level of arachidonic acid in the liver 
lipids by 35 % compared with control animals given an isocaloric diet with primarily beef tallow 
(Lawson et al., 1983). 
The Panel notes that it is generally recognised that the rat is not a good model for studying fatty acid 
metabolism in humans. 
The applicant provided preliminary results from a 4-week randomised controlled human trial in 72 
healthy women, measuring plasma concentrations of petroselinic acid after daily consumption of 
600 mg of coriander seed oil (3 x 200 mg/day, n = 24 or 600 mg/day, n = 24) or a placebo (paraffin 
oil, n = 24) (unpublished study report by Lissy et al. (2012)), which indicate that petroselinic acid is 
absorbed. The Panel notes that the information available from the graphs provided on the level of 
absorption of petroselenic acid were scarce, and that limited conclusions can be drawn from these 
data. 
8.2. Genotoxicity 
The coriander seed oil was tested using the in vitro bacterial reverse mutation assay (plate 
incorporation and pre-incubation methods) with Salmonella typhimurium strains (TA98, TA100, 
TA1535, TA1537, and TA102) with and without metabolic activation (compliant with OECD test 
guideline No 471 and GLP (Good Laboratory Practice)) (unpublished study report by Chalendard and 
Liang (2009a)). The coriander seed oil was tested as an emulsion, dispersed in ethanol. To account for 
the state of the test substance (i.e. emulsion), bacteria were exposed to concentrations of up to 
16 000 μg/plate of coriander seed oil. Coriander seed oil was tested negative for mutagenicity in the 
absence and presence of metabolic activation in the five S. typhimurium strains tested. 
The coriander seed oil was tested using an in vitro mouse lymphoma TK+/- assay (L5178Y mouse 
lymphoma cells), following a long exposure period (24 hours) without metabolic activation and with a 
short exposure period (four hours), with or without metabolic activation (compliant with OECD test 
guideline No 476 and GLP) (unpublished study report by Chalendard and Liang (2009b)). The 
coriander seed oil was in the form of an emulsion (in ethanol) and concentrations of up to 
8 000 μg/mL were tested. Coriander seed oil tested negative for genotoxicity in the absence and 
presence of metabolic activation. 
The Panel concludes that the NFI is not genotoxic under the conditions of these assays. 
8.3. Acute Toxicity Studies 
The applicant did not provide data on the acute toxicity of coriander seed oil. 
8.4. Subchronic/Chronic Toxicity Studies 
One study conducted with a coriander oil includes a number of parameters that can be used in a safety 
assessment, although it is not a conventional safety study (Richter et al., 1996). In this study, male 
Wistar rats (85-90 g) were divided into groups of 10 and fed a diet containing 12 % coriander oil 
(approximately 12 g/kg bw, see Section 8.1) and 2 % corn oil, for a period of 10 weeks. The coriander 
oil contained 72 % petroselinic acid. Considering the composition of the oil, the Panel assumes that it 
was derived from coriander seeds. Additional groups of rats were given 12 % high-oleic sunflower oil, 
sunflower oil, olive oil, or rapeseed oil. A control group (n = 5) was administered a standard diet with 
4 % fat. At termination, anatomical and histological examinations of the liver, heart, aorta, stomach 
and spleen were performed.  
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All high-fat diets induced fatty livers with total lipid contents of 7.1-9.7 %. At the histological 
examination of the livers, hepatocytes with mixed-size lipid vesicles, mainly periportal, were seen in 
all groups given high-fat diets. In the group given coriander seed oil, the fat infiltration was more 
pronounced (average degree: 2.3 vs. 1.6-1.9), and large macrovesicular lipid droplets (fatty cysts) were 
seen as well. Only a very low degree of these effects was seen in the control group. In various animals 
fed coriander seed oil, enlarged nuclei were observed in liver cells without fat infiltration when 
compared to animals fed standard diet. No such effect was observed in the other groups. No 
indications of inflammatory reactions were observed in these animals. Histological examination of the 
heart, aorta, stomach and spleen revealed no histopathological lesions in these organs. The authors 
suggest that the observed severe fat infiltration in the liver of coriander seed oil-fed rats could be due 
to the low activity of the liver lipase to hydrolyse triacylglycerols containing petroselinic acid, and the 
limited metabolism of petroselinic acid. In addition, it is suggested that the enlarged nuclei of some of 
the liver cells could have been caused by a stimulation in response to cell degeneration or cell death 
(e.g. as a result of fatty cyst formation).   
The Panel considers that the significant fat infiltrations observed in all groups except the control group 
is most likely a result of the high fat level in the diet. However, the Panel notes that the fat infiltration 
and histopathological alterations observed in the coriander seed oil group appeared to be more 
pronounced. 
The applicant commissioned a 13-week subchronic oral toxicity study in rats (unpublished study 
report by Giorgi et al. (2010)), which followed the OECD test guideline No 408 and the principles of 
GLP. The study was carried out by giving (oral gavage) 150, 450 or 1 000 mg/kg body weight per day 
of coriander seed oil to three groups of 10 male and 10 female Wistar Crl:WI (Han) rats for 13 weeks. 
A group of 10 rats per sex received the vehicle (1 % carboxymethylcellulose in water with 5 % Tween 
80) and served as the negative control. Two additional groups of five male and five female animals 
were administered the high dose or vehicle for 13 weeks, and received a standard rodent diet for four 
weeks thereafter (recovery group). Rats were housed in groups of five of the same sex. During the 
study, the following parameters were monitored: clinical condition, functional observation, body 
weight, food consumption, ophthalmic examination, haematology, blood chemistry, urinalysis, organ 
weight, macropathology and histopathological investigations. 
Mean body weight and body weight gains over the 13-week period were noted to be slightly lower 
(less than 10 %) in treated males, particularly at the low- and mid-dose levels compared to controls 
(not statistically significant). During the four week post-treatment period, significantly lower body 
weight gains were observed in some weeks in the high-dose males of the recovery group. The body 
weights of female rats were not affected. Food consumption was slightly lower (up to 10 %), but not 
statistically significant, in male and female rats given the coriander seed oil. The effect was more 
pronounced in the medium and high dose groups. The same tendency was seen for males but not 
females in the post-treatment period. The reduced food consumption of the dosed animals is most 
likely due to the daily intake of coriander seed oil through gavage. The decreased body weight gain of 
males is probably a consequence of the reduced feed intake, and is not considered to be adverse.  
In haematology, a statistically significant increased count of large unstained cells was seen for the 
medium and high dose group in males compared to the control group. No difference for this parameter 
was seen for the recovery group and females. A significantly higher activated partial thromboplastine 
time was seen in high dose males, but in the recovery group only. These are regarded as incidental 
findings.  
For the clinical chemistry parameters, a dose-dependent increase in serum glucose levels in males was 
observed, which reached statistical significance at the high-dose level (mean ± SD, control group: 
7.53 ± 1.24 mmol/L; low dose group: 7.59 ± 0.64 mmol/L; intermediate dose group: 
8.01 ± 0.05 mmol/L; high dose group: 10.00 ± 1.51 mmol/L). The glucose concentration in the male 
high dose group was reported to be beyond background values in male rats (6.25 ± 0.91 mmol/L), and 
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is probably a treatment-related effect. No effect on serum glucose levels was seen in the male recovery 
group and in females.  
A significant reduced sodium and increased creatinine level were seen for the high dose male group. 
For the medium and high dosed males a reduced total bilirubin level was observed. None of the above-
mentioned effects in relation to clinical chemistry was apparent in the recovery and female groups. All 
female dose groups had increased calcium levels, which showed no dose-response. Activity of 
aspartate aminotransferase was significantly reduced in the female high dose group. A significantly 
higher protein concentration was seen in the male recovery group compared to the control group. The 
observed differences in relation toclinical chemistry parameters were either seen in only one sex, were 
not dose-related, did not appear in the recovery group, or appeared only in the recovery group.  
For the urinalysis, a significant reduction in urine volume in all male test groups compared to controls 
was seen at the end of the treatment period. The decreased urine volume could be a physiological 
response, but no measurements of water intake were performed during the study that could clarify this.  
The relative mean thymus weights were significantly greater in mid-dose males compared to controls. 
Given the absence of a dose-dependent response, this was not considered to be biologically significant. 
In females, absolute brain and heart weights were significantly lower compared to controls, but only in 
the recovery group. No significant differences were seen for any organ, including the liver, at the 
macro- and microscopic examinations.  
Although the effect on glucose concentrations observed in male rats was not accompanied by any 
toxicologically relevant findings, the biological relevance of this effect is unclear, and therefore the 
Panel considers that the dose level of 450 mg/kg bw per day is the NOAEL in this study. 
8.5. Developmental and Reproductive Toxicity Studies 
The applicant did not provide data on the reproductive and developmental toxicity of coriander seed 
oil. 
8.6. Human Studies  
The applicant provided results from a human clinical study conducted to investigate potential 
beneficial effects of the NFI (unpublished study report by Hoffmann (2013)). In this controlled 
randomised double-blind study in healthy Caucasian women aged between 18 and 50 years, one group 
received the test product coriander seed oil (600 mg/day, n = 72) and the other group received the 
placebo, paraffin oil (n = 71), for six months. Blood samples were collected at baseline (day 1), day 
20-28, day 76-84 and day 160-168 (termination of study) and analysed for haematological parameters, 
triglycerides, cholesterol, urea, creatinine and glucose concentrations. No significant difference 
between the placebo group and the coriander seed oil group was observed for any of the blood 
parameters. The coriander seed oil was well tolerated and no adverse effects related to treatment with 
coriander seed oil were observed.  
In response to an MS comment, the applicant performed analyses of serum fatty acid content in a sub-
group of 16 subjects of the placebo group and 20 subjects of the treatment group (unpublished study 
results). Concentrations of arachidonic acid, docosahexaenoic acid (DHA), oleic acid and cis isomers, 
saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids 18:2 and 18:3, long-
chain polyunsaturated fatty acids and total fatty acids were measured. In both sub-groups, no 
significant change from baseline was observed for any parameter. No between-group comparisons 
were performed. The applicant also provided raw data of serum content of C18:1 fatty acid isomers in 
both sub-groups (unpublished study results).  
The Panel considers that no treatment-related adverse effects were observed in healthy women 
consuming the NFI at a dose of 600 mg/day for six months.  
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9. Allergenicity 
Allergenicity (including dermatitis) to coriander has been previously described in case reports 
(Suhonen et al., 1979; Kanerva and Soini, 2001; Ebo et al., 2006). Sensitisation to the Apiaceae family 
of spices was reported to be high following skin prick tests in children (< 15 years old) and adults 
(Moneret-Vautrin et al., 2002). A case report of a 26 year-old woman who presented with multiple 
systemic reactions including urticaria and laryngeal angioedema following ingestion of carrots cooked 
in sunflower oil and margarine was identified (Moneret-Vautrin et al., 2002). Subsequent food 
allergen tests revealed highly positive results to Apiaceae and Compositae. A double-blind, placebo-
controlled food challenge (DBPCFC) to 265 mg coriander resulted in sneezing and rhinorrhea. Nasal 
dysfunction increased 1 hour 30 minutes after ingestion. Conjunctivitis occurred an hour later.  
The applicant indicates that no reports of allergenicity to coriander seed oil have been reported in the 
literature to date. 
The applicant notes that the ingredient intended for use as a food supplement is the seed oil, rather 
than any protein containing fraction. Based on UK NDNS survey data, the applicant estimated a daily 
mean background exposure to coriander seed proteins from the diet of around 10-15 mg. Assuming the 
sensitivity of the Kjeldahl test method, the applicant calculated that, assuming an intake of 600 mg 
coriander seed oil, an exposure of 0.6 mg per person per day (or 0.2 mg per serving) of coriander seed 
protein would result from consumption of the NFI, which is much lower than the amount of protein 
inducing allergic reactions in the DBPCFC study by Moneret-Vautrin et al. (2002). It would therefore 
constitute no additional risk of allergenicity to the general population.  
The Panel considers that the risk of allergic reactions to the NFI is not higher than that of other 
products containing coriander seeds.  
DISCUSSION 
Coriander seed oil is a triglyceride oil which is produced from the seeds of the coriander plant 
Coriandrum sativum L.. Petroselinic acid, a monounsaturated fatty acid, is the major fatty acid of 
coriander seed oil (60-75 %). The NFI also contains small quantities of other fatty acids such as 
linoleic acid, oleic acid, palmitic acid and stearic acid. 
The Panel notes that the information provided on the manufacturing process, as well as on the 
composition, specification and nutritional value of the NFI, is sufficient, and does not raise safety 
concerns. 
Coriander seed oil is proposed for use as a food supplement for healthy adults at a maximum level of 
600 mg per day. The estimated mean and 95
th
 percentile daily adult intake of coriander seed oil from 
intake of coriander seed is around 20 mg and 100 mg for all-users, respectively. The anticipated intake 
of the NFI is about 30 and 6 times higher than estimated background intake, respectively. The 
estimated mean and 95
th
 percentile daily adult intake of petroselinic acid from all background sources 
is around 30 mg and 100 mg, respectively. The anticipated intake of petroselinic acid through the NFI 
is about 15 and 5 times higher than the estimated background intake of this fatty acid, respectively. 
The anticipated intake of the NFI will therefore be significantly higher than current background 
consumption of coriander seed oil and petroselinic acid.   
Triacylglycerols containing petroselinic acid appear to be hydrolysed in vivo and absorbed from the 
small intestine, although at a slower rate than other fatty acids of similar chain length.  
The Panel notes that significantly increased liver weight and marked-to-severe fat infiltration in the 
liver were seen in a 10-week rat study using a high dose level of coriander seed oil (12 % in the diet). 
In addition, changes in the fatty acid composition of hepatic and adipose tissues were observed, 
including lower concentrations of arachidonic acid. These effects were to some extent to be expected 
when feeding animals with high levels of an oil that has a specific fatty acid profile. In the same 
studies, feeding of olive oil, rapeseed oil, and sunflower oil at the same level also led to marked fat 
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infiltration in the liver, although not as severe as that seen for coriander seed oil. The dose level of 
coriander seed oil in these studies was approximately 12 g/kg bw per day, which is more than a 
thousand fold higher than the exposure to the NFI estimated under the proposed conditions of use as a 
food supplement (i.e. 600 mg/day or 8.6 mg/kg bw/day for a 70 kg person).  
Although the effect on glucose concentrations observed in male rats in the subchronic 13-week  
toxicity study was not accompanied by any toxicological relevant findings, the biological relevance of 
this effect is unclear, and therefore the Panel considers that the dose level of 450 mg/kg bw per day is 
the NOAEL in this study. This dose is about 50 fold higher than the anticipated exposure under the 
proposed conditions of use. 
Data from the controlled randomised double-blind study in healthy women where participants received 
coriander seed oil (600 mg/day) for six months showed no effect on haematological parameters, nor on 
blood glucose and fatty acid concentrations, including arachidonic acid.  
The Panel considers the nature of the NFI, the fact that the margin between the intended intake and the 
NOAEL of 450 mg/kg bw per day in the subchronic 13-week rat toxicity study is sufficient, and the 
fact that no adverse effect was observed in one human study at the intended dose level. 
CONCLUSIONS 
The Panel concludes that the novel food ingredient, coriander seed oil, is safe under the proposed uses 
and use levels.  
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1. Dossier “Application for the Approval of Coriander Seed Oil for Use in Foods for the General 
Population and Food Supplements Under Regulation (EC) No 258/97 of the European 
Parliament and of the Council of 27 January 1997 Concerning Novel Foods and Novel Food 
Ingredients” received on 19 February 2013. Submitted by Nestec Ltd. on 21 July 2011. 
Additional data were provided on 02 July 2013. 
2. Letter from the European Commission to the European Food Safety Authority with the request 
for an opinion on the safety of „Coriander Seed Oil‟. SANCO/E6/Ak/ks D (2013) 196714, dated 
14 February 2013.  
3. Initial assessment report carried out by the Food Safety Authority of Ireland: „Safety 
Assessment of Coriander Seed Oil‟. 
4. Member States‟ comments and objections. 
5. Response by the applicant to the initial assessment report and the Member States' comments and 
objections. 
REFERENCES 
Burdock GA and Carabin IG, 2009. Safety assessment of coriander (Coriandrum sativum L.) essential 
oil as a food ingredient. Food and Chemical Toxicology, 47, 22-34. 
Caster WO, Mohrhauer H and Holman RT, 1966. Effects of twelve common fatty acids in the diet 
upon the composition of liver lipid in the rat. Journal of Nutrition, 89, 217-225. 
Chalendard M and Liang C, 2009a. Coriander Seed Oil, Type C – Bacterial Reverse Mutation Test 
(Plate Incorporation and Pre-incubation Methods).  (Study number: AA78240). Unpublished 
proprietary study report. Prepared by MDS Pharma Services, Lyon, France for Nestlé Research 
Center, Chemical Food Safety, Quality & Safety Department, Lausanne, Switzerland. 49 pp. 
Chalendard M and Liang C, 2009b. Coriander Seed Oil, Type C – In Vitro Mammalian Cell Gene 
Mutation Test on L5178Y Mouse Lymphoma Cells TK+/- (Microwell Method). (Study number: 
AA78241). Unpublished proprietary study report. Prepared by MDS Pharma Services, Lyon, 
Safety of Coriander Seed Oil 
 
18 EFSA Journal 2013;11(10):3422 
France for Nestlé Research Center, Chemical Food Safety, Quality & Safety Department, 
Lausanne, Switzerland. 70 pp. 
Council of Europe, 1981. Coriander. In: Flavouring Substances and Natural Sources of Flavourings, 
3rd ed. Strasbourg, France, p. 76. 
Ebo DG, Bridts CH, Mertens MH and Stevens WJ, 2006. Coriander anaphylaxis in a spice grinder 
with undetected occupational allergy. Acta Clinica Belgica, 61, 152-156. 
EFSA SC (EFSA Scientific Committee), 2012. Guidance on selected default values to be used by the 
EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. 
EFSA Journal 2012;10(3):2579, 32 pp. doi:10.2903/j.efsa.2012.2579. 
Giorgi H, Drevon-Gaillot E, Howroyd P and Liang C, 2010. Coriander Seed Oil, Type C-13-week 
Oral (Gavage) Toxicity Study in Rat Followed by a 4-week Treatment-Free Period. (Study number: 
AA78242). Unpublished proprietary study report. Prepared by MSDS Pharma Services for Nestlé 
Research Center, Chemical Food Safety, Quality & Safety Department, Lausanne, Switzerland. 540 
pp. 
Health Canada, 2007. Search results for „Coriander oil‟. In: Natural Health Products Ingredients 
Database. Health Canada, Natural Health Products Directorate (NHPD), Ottawa, Ontario; 2007. 
Available online: http://webprod.hc-sc.gc.ca/nhpidbdipsn/ingredReq.do?id=3855&lang=eng 
Health Canada, 2009. Search results for product name „Coriander‟ (Natural Product number: 
80015479). In: Licensed Natural Health Products Database. Health Canada, Natural Health 
Products Directorate (NHPD), Ottawa, Ontario. Available online: http://webprod.hc-
sc.gc.ca/lnhpd-bdpsnh/start-debuter.do?lang=eng 
Heimermann WH, Holman RT, Gordon DT, Kowalyshyn DE and Jensen RG, 1973. Effect of double 
bond position in octadecenoates upon hydrolysis by pancreatic lipase. Lipids, 8, 45-47. 
Hoffmann R, 2013. Evaluation of the effect of a nutritional supplement versus placebo on hair loss. 
Study N. BTS520/10//10E Coriander 2. Proprietary unpublished study report., 178 pp. 
Hoy CE and Holmer G, 1981. Incorporation of cis-octadecenoic acids into the rat liver mitochondrial 
membrane phospholipids and adipose tissue triglycerides. Lipids, 16, 102-108. 
Kanerva L and Soini M, 2001. Occupational protein contact dermatitis from coriander. Contact 
Dermatitis, 45, 354-355. 
Kiralan M, Calikoglu E, Ipek A, Bayrak A and Gurbuz B, 2009. Fatty acid and volatile oil 
composition of different coriander (Coriandrum sativum) registered varieties cultivated in Turkey. 
Chemistry of Natural compounds, 45, 100-102. 
Lawson LD, Hill EG and Holman RT, 1983. Suppression of arachidonic acid in lipids of rat tissues by 
dietary mixed isomeric cis and trans octadecenoates. Journal of Nutrition, 113, 1827-1835. 
Lissy M, Koch M, Lehnick D, Gonzalo F and Piskol G, 2012. Study Protocol. Comparative 
bioavailability study of petroselinic acid after coriander seed oil consumption. Study No 
11.15.NRC., 47 pp. 
Moneret-Vautrin DA, Morisset M, Lemerdy P, Croizier A and Kanny G, 2002. Food allergy and IgE 
sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). Allergie et 
Immunologie, 34, 135-140. 
Opdyke DLJ, 1973. Monographs on fragrance raw materials: coriander oil. Food and Cosmetics 
Toxicology, 11, 1077. 
Richter KD, Mukherjee KD and Weber N, 1996. Fat infiltration in liver of rats induced by different 
dietary plant oils: high oleic-, medium oleic- and high petroselinic acid-oils. Zeitschrift fur 
Ernahrungswissenschaft, 35, 241-248. 
Safety of Coriander Seed Oil 
 
19 EFSA Journal 2013;11(10):3422 
Seher A and Fiebig H-J, 1983. Stereospezifische Analyse von Triacylglycerinen mit selten 
vorkommenden Fettsäuren. [Stereospecific analysis of triacylglycerides with rarely occurring fatty 
acids]. Fette, Seifen, Anstrichmittel 85, 333-338. 
Suhonen R, Keskinen H, Bjorksten F, Vaheri E and Zitting A, 1979. Allergy to coriander. A case 
report. Allergy, 34, 327-330. 
Therapeutic Goods Administration, 2007. Substances That May Be Used in Listed Medicines in 
Australia. Therapeutic Goods Administration (TGA), Australian Government Department of 
Health and Aging. Available online: http://www.tga.gov.au/cm/listsubs.pdf 
U.S. FDA, 2011. Search results for 'coriander oil '. In: Inactive Ingredient Search for Approved Drug 
Products. U.S. Food and Drug Administration (U.S. FDA), Center for Drug Evaluation and 
Research (CDER), Office of Generic Drugs, Rockville. Available online: 
http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm 
Weber N, Richter KD, Schulte E and Mukherjee KD, 1995. Petroselinic acid from dietary 
triacylglycerols reduces the concentration of arachidonic acid in tissue lipids of rats. Journal of 
Nutrition, 125, 1563-1568. 
Weber N, Vosmann K, Brühl L and Mukherjee KD, 1997. Metabolism of dietary petroselinic acid: a 
dead-end metabolite of desaturation/chain elongation reactions. Nutrition Research, 17, 89-97. 
Weber N, Schonwiese S, Klein E and Mukherjee KD, 1999. Adipose tissue triacylglycerols of rats are 
modulated differently by dietary isomeric octadecenoic acids from coriander oil and high oleic 
sunflower oil. Journal of Nutrition, 129, 2206-2211. 
Weber N, Klein E and Mukherjee KD, 2003. Stereospecific incorporation of palmitoyl, oleoyl and 
linoleoyl moieties into adipose tissue triacylglycerols of rats results in constant sn-1:sn-2:sn-3 in 
rats fed rapeseed, olive, conventional or high oleic sunflower oils, but not in those fed coriander oil. 
Journal of Nutrition, 133, 435-441. 
 
  
Safety of Coriander Seed Oil 
 
20 EFSA Journal 2013;11(10):3422 
ABBREVIATIONS 
CSO  corander seed oil 
DBPCFC double-blind, placebo-controlled, food challenge 
DHA  docosahexaenoic acid 
GLP  good laboratory practice 
HACCP hazard analysis and critical control points 
HDL  high density lipid 
HOS  high-oleic sunflower oil 
HPLC  high performance liquid chromatography 
IUPAC  International Union of Pure and Applied Chemistry 
LOQ  limit of quantification 
MS  Member State 
NDNS  National Diet and Nutrition Survey 
NF(I)  Novel Food (Ingredient) 
NOAEL no observed adverse effect level 
OECD  Organisation for Economic Co-operation and Development 
PA  petroselinic acid 
PCBs  polychlorinated biphenyls 
SD  standard deviation 
UFC  colony forming unit 
